In Vitro and In Vivo Antibacterial Activity of Gliotoxin Alone and in Combination with Antibiotics against

Animals Anti-Bacterial Agents / pharmacology Caenorhabditis elegans Disease Models, Animal Disk Diffusion Antimicrobial Tests Dose-Response Relationship, Drug Drug Resistance, Multiple, Bacterial Drug Therapy, Combination Gliotoxin / pharmacology Methicillin-Resistant Staphylococcus aureus / drug effects Staphylococcal Infections / drug therapy Vancomycin / pharmacology
MRSA Staphylococcus aureus VISA antibiotic gliotoxin resistance synergism vancomycin

Journal

Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765

Informations de publication

Date de publication:
23 01 2021
Historique:
received: 20 12 2020
revised: 19 01 2021
accepted: 21 01 2021
entrez: 27 1 2021
pubmed: 28 1 2021
medline: 2 7 2021
Statut: epublish

Résumé

Multidrug-resistant bacteria such as methicillin-resistant

Identifiants

DOI: 10.3390/toxins13020085 PMID: 33498622 PMC: PMC7911140
pubmed: 33498622
pii: toxins13020085
doi: 10.3390/toxins13020085
pmc: PMC7911140
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Gliotoxin 67-99-2
Vancomycin 6Q205EH1VU

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Gobierno de Aragón
ID : Group B29_17R
Organisme : European Regional Development Fund
ID : NA
Organisme : Ministerio de Ciencia, Innovación y Universidades
ID : SAF2017-83120-C2-1-R
Organisme : ASPANOA
ID : NA
Organisme : Gilead Sciences
ID : GLD18/00100
Organisme : Fundación Agencia Aragonesa para la Investigación y el Desarrollo
ID : NA
Organisme : Fondo Garantıa Empleo Juvenil/INAEM
ID : NA
Organisme : DGA predoctoral contract
ID : NA
Organisme : Juan de la Cierva contract of Spanish Ministry of Economy and Competitiveness
ID : FJCI-2017-31629

Références

Clin Microbiol Rev. 2010 Jan;23(1):99-139
pubmed: 20065327
Intern Med J. 2005 Dec;35 Suppl 2:S97-105
pubmed: 16271065
Toxins (Basel). 2018 Jun 19;10(6):
pubmed: 29921792
J Antibiot (Tokyo). 2006 Apr;59(4):248-50
pubmed: 16830893
Microbiology (Reading). 2005 Apr;151(Pt 4):1021-1032
pubmed: 15817772
Arch Intern Med. 2009 Mar 9;169(5):463-73
pubmed: 19273776
J Clin Nurs. 1995 Jan;4(1):5-12
pubmed: 7704377
J Cell Biol. 2006 Aug 14;174(4):509-19
pubmed: 16893972
Clin Microbiol Rev. 2018 Sep 12;31(4):
pubmed: 30209034
Development. 1992 Nov;116(3):755-66
pubmed: 1289064
Clin Microbiol Infect. 2001;7 Suppl 4:8-15
pubmed: 11688538
J Antimicrob Chemother. 2012 Aug;67(8):1843-9
pubmed: 22535621
Vet Dermatol. 2009 Oct;20(5-6):383-96
pubmed: 20178475
Front Microbiol. 2018 Jun 05;9:1205
pubmed: 29922270
Int J Environ Res Public Health. 2014 Aug 29;11(9):8996-9007
pubmed: 25177823
J Antimicrob Chemother. 2003 Jul;52(1):1
pubmed: 12805255
Clin Microbiol Rev. 2015 Jul;28(3):603-61
pubmed: 26016486
Mycoses. 1998 Mar-Apr;41(3-4):97-104
pubmed: 9670759
Yale J Biol Med. 2017 Jun 23;90(2):269-281
pubmed: 28656013
Clin Infect Dis. 2003 Feb 15;36(4):429-39
pubmed: 12567300
Mol Immunol. 1987 Jan;24(1):47-55
pubmed: 2441247
Nat Rev Dis Primers. 2018 May 31;4:18033
pubmed: 29849094
Arch Intern Med. 2006 Oct 23;166(19):2138-44
pubmed: 17060545
Open Med (Wars). 2018 Oct 22;13:475-486
pubmed: 30426085
Transplantation. 1988 Jul;46(1):120-5
pubmed: 2455943
Antimicrob Agents Chemother. 1999 Jul;43(7):1756-8
pubmed: 10390236
Lancet. 1998 Feb 21;351(9102):602
pubmed: 9492814
BMC Complement Altern Med. 2014 Jan 06;14:4
pubmed: 24393217
Microbiol Mol Biol Rev. 2002 Sep;66(3):447-59, table of contents
pubmed: 12208999
Intern Med J. 2005 Dec;35 Suppl 2:S17-24
pubmed: 16271058
Gen Pharmacol. 1996 Dec;27(8):1311-6
pubmed: 9304400
J Clin Invest. 2014 Jul;124(7):2836-40
pubmed: 24983424
PLoS One. 2011;6(9):e25321
pubmed: 21966496
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Am J Health Syst Pharm. 2020 May 19;77(11):835-864
pubmed: 32191793
J Infect Dis. 2008 May 1;197(9):1226-34
pubmed: 18422434
Infect Ecol Epidemiol. 2012;2:
pubmed: 22957125
Chem Biol. 2011 Apr 22;18(4):542-52
pubmed: 21513890
Lancet. 1997 Dec 6;350(9092):1670-3
pubmed: 9400512
Fungal Genet Biol. 2012 Apr;49(4):302-12
pubmed: 22405895
Mar Drugs. 2014 Nov 24;12(11):5657-76
pubmed: 25421322
Mutat Res. 2002 Sep 26;520(1-2):161-70
pubmed: 12297156
Ann Fam Med. 2006 Mar-Apr;4(2):132-7
pubmed: 16569716
Ugeskr Laeger. 1961 Mar 17;123:384-6
pubmed: 13697147

Auteurs

Patricia Esteban (P)

Fundacion Instituto de Investigacion Sanitaria Aragon (IIS Aragon), Biomedical Research Centre of Aragon (CIBA), 50009 Zaragoza, Spain.

Sergio Redrado (S)

Instituto de Carboquımica ICB-CSIC, 50018 Zaragoza, Spain.

Laura Comas (L)

Instituto de Carboquımica ICB-CSIC, 50018 Zaragoza, Spain.
ORCID: 0000-0002-3843-1231

M Pilar Domingo (MP)

Instituto de Carboquımica ICB-CSIC, 50018 Zaragoza, Spain.
ORCID: 0000-0002-6829-8769

M Isabel Millán-Lou (MI)

Department of Microbiology, Hospital Universitario Miguel Servet, IIS Aragón, 50009 Zaragoza, Spain.

Cristina Seral (C)

Department of Microbiology, University Clinic Hospital Lozano Blesa, 50009 Zaragoza, Spain.
Department of Microbiology, Pediatrics, Radiology and Public Health, University of Zaragoza, 50009 Zaragoza, Spain.

Sonia Algarate (S)

Department of Microbiology, University Clinic Hospital Lozano Blesa, 50009 Zaragoza, Spain.

Concha Lopez (C)

Department of Microbiology, Hospital Universitario Miguel Servet, IIS Aragón, 50009 Zaragoza, Spain.

Antonio Rezusta (A)

Department of Microbiology, Hospital Universitario Miguel Servet, IIS Aragón, 50009 Zaragoza, Spain.

Julian Pardo (J)

Fundacion Instituto de Investigacion Sanitaria Aragon (IIS Aragon), Biomedical Research Centre of Aragon (CIBA), 50009 Zaragoza, Spain.
Department of Microbiology, Pediatrics, Radiology and Public Health, University of Zaragoza, 50009 Zaragoza, Spain.
Aragon I+D Foundation (ARAID), 50018 Zaragoza, Spain.

Maykel Arias (M)

Instituto de Carboquımica ICB-CSIC, 50018 Zaragoza, Spain.

Eva M Galvez (EM)

Instituto de Carboquımica ICB-CSIC, 50018 Zaragoza, Spain.
ORCID: 0000-0001-6928-5516

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › In Vitro and In Vivo Antibacterial Activity of...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › In Vitro and In Vivo Antibacterial Activity of...
questionsmedicales.fr › Eucaryotes › Animaux › Invertébrés › Helminthes › Nematoda › Chromadorea › Rhabditida › Rhabditoidea › Caenorhabditis › Caenorhabditis elegans › In Vitro and In Vivo Antibacterial Activity of...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › In Vitro and In Vivo Antibacterial Activity of...
questionsmedicales.fr › Techniques d'investigation › Techniques de laboratoire clinique › Techniques microbiologiques › Tests d'agents antimicrobiens par diffusion à partir de disques › In Vitro and In Vivo Antibacterial Activity of...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Relation dose-effet des médicaments › In Vitro and In Vivo Antibacterial Activity of...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Multirésistance aux médicaments › Multirésistance bactérienne aux médicaments › In Vitro and In Vivo Antibacterial Activity of...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › In Vitro and In Vivo Antibacterial Activity of...
questionsmedicales.fr › Facteurs biologiques › Toxines biologiques › Mycotoxines › Gliotoxine › In Vitro and In Vivo Antibacterial Activity of...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Cocci à Gram positif › Staphylococcaceae › Staphylococcus › Staphylococcus aureus › Staphylococcus aureus résistant à la méticilline › In Vitro and In Vivo Antibacterial Activity of...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à staphylocoques › In Vitro and In Vivo Antibacterial Activity of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Glycopeptides › Vancomycine › In Vitro and In Vivo Antibacterial Activity of...